

# Key Information Document

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

Name: Sectoral Biotech Opportunities Fund (the "Sub-Fund"), a sub-fund of Protea Fund (the "Fund")  
ISIN: LU1176838347  
Class: PF EUR (the "Class")  
Product manufacturer: FundPartner Solutions (Europe) S.A. (the "Management Company"), part of Pictet Group.  
Website: <https://assetservices.group.pictet/asset-services/fund-library/>

Call +352 467171-1 for more information.

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising FundPartner Solutions (Europe) S.A. in relation to this Key Information Document.

This PRIIP is authorised in Luxembourg.

FundPartner Solutions (Europe) S.A. is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

This key information document is accurate as at 19<sup>th</sup> February 2024.

## What is this product?

### TYPE OF PRODUCT

The product is a sub-fund of Protea Fund, an Undertaking for Collective Investment in Transferable Securities (UCITS) incorporated as a variable capital investment company (SICAV) under the laws of Luxembourg.

### TERM

The Sub-Fund is established for an unlimited duration. However, the board of directors may also propose to dissolve a sub-fund at a general meeting of that sub-fund.

### OBJECTIVES

#### Objectives and investment policy

The Sub-Fund is geared to private and/or institutional investors with a long-term investment horizon, who wish to invest in companies worldwide, conducting business in the biotech sector, while being aware of the associated price fluctuations.

This Sub-Fund invests primarily in innovative biotech companies developing novel drugs in therapeutic areas with large unmet medical needs. Investments are made across all market caps, with significant exposure to mid- and small-cap biotech companies, due to their high degree of innovation. Novel and differentiated treatments benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in biotech has created large new markets, and tremendous commercial potential remains in many diseases and novel therapeutic modalities, such as mRNA and gene therapy.

While respecting the principle of risk diversification, the Sub-Fund's net assets are primarily invested in equities and equity-related securities (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), European Depositary Receipts (EDRs)) issued by innovative small, mid and large cap biotech companies which are active in the human medicine sector.

While no geographical restrictions apply, the Sub-Fund's investments are centered in North America and Western Europe.

The Sub-Fund may invest in transferable securities and money market instruments from new issues to benefit from particularly innovative projects in the healthcare sector, in particular in innovative projects in the drugs sector.

Up to 10% of the Sub Fund's net assets may be invested in Special Purpose Acquisition Companies.

The Sub-Fund may invest up to 33% of its net assets, via Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, in China A-Shares. Up to 33% of the Sub-Fund's net assets may be invested outside the aforementioned investment universe including, but not limited to equities of issuers of other business segments than biotech, in fixed and variable interest securities. The Sub-Fund may not invest more than 10% of its net assets in other UCIs or UCITS.

**Derivatives** For hedging and for investment purposes, the Sub-Fund may use all types of financial derivative instruments traded on a regulated market and/or OTC.

**Benchmark** The Sub-Fund is actively managed. The benchmark index Nasdaq Biotech Index is mentioned for performance comparison purposes. The Sub-Fund does not track the index and can deviate significantly or entirely from the benchmark index.

**ESG information** This Sub-Fund is managed to promote, among other characteristics, a combination of environmental and social characteristics within the meaning of article 8 of SFDR, but if it does not have as its objective Sustainable Investments, the Sub-Fund will invest at least 30% of its NAV into Sustainable Investments with a social objective.

**Dividend Policy** This Class is cumulative. Dividend distributions are not planned.

**Share Class Currency** The currency of the Class is EUR.

The recommended holding period of this product is determined to allow sufficient time for this product to reach its objectives and avoiding short term market fluctuations.

The return of the product is determined using the Net Asset Value (the "NAV") calculated by FundPartner Solutions (Europe) S.A. (the "Administrative Agent"). This return depends mainly on the market value fluctuations of the underlying investments.

### INTENDED RETAIL INVESTORS

The product is suitable for retail investors with limited knowledge of the underlying financial instruments and no financial industry experience. The product is compatible with investors who may bear capital losses and who do not need capital guarantee. The product is compatible with clients looking for growing their capital and who wish to hold their investment over 5 years.

### OTHER INFORMATION

**Depositary** Bank Pictet & Cie (Europe) AG, succursale de Luxembourg (the "Depositary").

**Asset segregation** The assets and liabilities of each sub-fund are segregated by law, which means that the performance of the assets in other sub-funds does not influence the performance of your investment.

**Dealing** The NAV for this Class is calculated on each Business Day, on the basis of the pricing of the preceding business day ("the Valuation Day"). For any subscription or redemption request received by the Fund, prior to 4 p.m. Luxembourg time, on the Valuation Day, the NAV calculated based on the pricing of the Valuation Day will be applicable.

**Switching** Shareholders may apply for any shares of any sub-funds to be converted into shares of another sub-fund, provided that the conditions for accessing the target class or sub-fund are fulfilled with respect to this sub-fund, on the basis of their respective NAV calculated on the Valuation Day following receipt of the conversion request. The redemption and subscription costs connected with the conversion may be charged to the shareholder as indicated in the prospectus. For more details about how to switch between sub-funds, please refer to the prospectus.

**Additional Information** More detailed information on the Fund, such as the prospectus, other classes, the key information, the latest NAV, the articles of incorporation as well as the latest annual and semi-annual report, can be obtained free of charge, in English, from the Administrative Agent, the distributors, the Management Company or online at [www.fundsquare.net](http://www.fundsquare.net).

This key information document describes the Class of one sub-fund of the Fund. For more information about other sub-funds, please refer to the prospectus and periodic reports that are prepared for the entire Fund.

## What are the risks and what could I get in return?

### Risk indicator

1	2	3	4	5	6	7
---	---	---	---	---	---	---

Lower risk

Higher risk



The risk indicator assumes you keep the product for 5 years.

The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. The essential risks of the investment fund lie in the possibility of depreciation of the securities in which the fund is invested.

### Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable proxy over the last 10 years. Markets could develop very differently in the future.

<b>Recommended holding period (RHP): Example investment</b>	<b>5 years EUR 10,000</b>	
	<b>If you exit after 1 year</b>	<b>If you exit after 5 years</b>

Scenarios				
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.			
<b>Stress scenario</b>	<b>What you might get back after costs</b> Average return each year	EUR 5,620 -43.8%	EUR 1,040 -36.4%	
<b>Unfavourable scenario</b>	<b>What you might get back after costs</b> Average return each year	EUR 6,250 -37.5%	EUR 7,350 -6.0%	This type of scenario occurred for an investment in the product between March 2015 and March 2020.
<b>Moderate scenario</b>	<b>What you might get back after costs</b> Average return each year	EUR 10,190 1.9%	EUR 9,310 -1.4%	This type of scenario occurred for an investment in the proxy then the product between December 2014 and December 2019.
<b>Favourable scenario</b>	<b>What you might get back after costs</b> Average return each year	EUR 14,900 49.0%	EUR 16,840 11.0%	This type of scenario occurred for an investment in the product between June 2016 and June 2021.

The stress scenario shows what you might get back in extreme market circumstances.

## What happens if FundPartner Solutions (Europe) S.A. is unable to pay out?

The Management Company is not making any payment to you in relation to the Sub-Fund and you would still be paid in case of a default from the Management Company.

The Sub-Fund's assets are held with a separate company, the Depository, so the Sub-Fund's ability to pay out would not be affected by the insolvency of the Management Company. However, in the event of the Depository's insolvency, or its delegates, the Sub-Fund may suffer a financial loss. However, this risk is mitigated to a certain extent by the fact the Depository is required by law and regulation to segregate its own assets from the assets of the Sub-Fund. The Depository will also be liable to the Sub-Fund or its investors for any loss arising from, among other things, its negligence, fraud or intentional failure properly to fulfill its obligations (subject to certain limitations).

If the Sub-Fund is terminated or wound up, the assets will be liquidated and you will receive an appropriate share of any proceeds but you may lose part or all of your investment.

There is no compensation or guarantee scheme protecting you from a default of the Depository.

## What are the costs?

**The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.**

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- EUR 10,000 is invested

Investment of EUR 10,000	If you exit after 1 year	If you exit after 5 years
<b>Total costs</b>	EUR 236	EUR 1,169
<b>Annual cost impact (*)</b>	2.4%	2.4%

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 1.0% before costs and -1.4% after costs.

#### Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	We do not charge an entry fee for this Class. The person selling you this product may charge up to 2.00%.	Up to EUR 200
Exit costs	We do not charge an exit fee for this Class.	EUR 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	2.13% of the value of your investment per year. This is an estimate based on actual costs over the last year.	EUR 213
Transaction costs	0.23% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	EUR 23
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	EUR 0

Conversions between sub-funds are subject to a commission of maximum 1% of the NAV of the shares to be converted.

## How long should I hold it and can I take my money out early?

#### Recommended holding period (RHP): 5 years.

The RHP was chosen to allow sufficient time for this product to reach its objectives and avoiding short term market fluctuations.

The NAV for this Class is calculated on each Business Day, on the basis of the pricing of the preceding business day ("the Valuation Day"). For any subscription or redemption request received by the Fund, prior to 4 p.m. Luxembourg time, on the Valuation Day, the NAV calculated based on the pricing of the Valuation Day will be applicable.

## How can I complain?

In the event a natural or legal person wishes to file a complaint with the Fund in order to recognize a right or to redress a harm, the complainant should address a written request that contains description of the issue and the details at the origin of the complaint, either by email or by post, in an official language of their home country to the following address:

FundPartner Solutions (Europe) S.A.,  
15 Avenue J.F. Kennedy,  
L-1855 Luxembourg  
pfcs.lux@pictet.com

<https://www.pictet.com/ch/en/legal-documents-and-notes/key-information-document-complaint-procedure>

## Other relevant information

More detailed information on the Fund, such as the prospectus, the articles of incorporation, the latest annual and semi-annual report as well as the latest NAVs per share, can be obtained free of charge, in English from the Administrative Agent, the distributors, the Fund or online at [www.fundsquare.net](http://www.fundsquare.net).

The past performance over the last 8 years and the previous performance scenarios are available on the link [https://download.alphaomega.lu/perfscenario\\_LU1176838347\\_LU\\_en.pdf](https://download.alphaomega.lu/perfscenario_LU1176838347_LU_en.pdf)